ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva Targets Big Cuts In Staffing

by Ann M. Thayer
October 14, 2013 | APPEARED IN VOLUME 91, ISSUE 41

Teva Pharmaceutical Industries is accelerating a cost-cutting program put in place last December. By the end of 2014, the Israeli company will reduce its workforce by about 10%, or 5,000 employees. Through job cuts, asset sales, and improved manufacturing efficiency, it is targeting $2.0 billion in annual savings by the end of 2017. Known primarily as a generic drug firm, Teva has been building its R&D programs and will put some of the savings into programs for complex generics and specialty medicines. The announcement comes soon after Merck & Co. said it would cut 16,000 jobs, nearly 20% of its workforce.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment